1. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298(11):1312-22.
2. Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol. 2008 Oct;52(4):300-5.
3. Chazov EI, Dedov II. Cardiac and endocrine aspects of amiodarone therapy in modern practice of heart arrhythmia disorders treatment. Doctors manual. Moscow, 2005. Russian. (Чазов Е.И., Дедов И.И. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритмов сердца. Пособие для врачей. Москва, 2005).
4. Bogazzi F, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010; 95:2529-2535
5. Martino E, Bartalena ME, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. EndocrRev. 2001; 22:240-254.
6. Ahmed S, Van Gelder IC, Wiesfeld ACP et al. Determinations and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011; 75:388-394.
7. Beddows SA, Page SR, Taylor AH, et al Cytotoxic Effects of Amiodarone and Desethylamiodarone on Human Thyrocytes. Biochem Pharmacol. 1989;38:4397-403.
8. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct;106(4 Pt 2):840-7.
9. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005; 118: 706-14.
10. Fukuchi H, Nakashima M, Araki R, et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. J Clin Pharm Ther. 2009; 34: 329-36.
11. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone induced thyrotoxicosis and hypothyroidism. Am J Med. 1991; 91:507-511.
12. Yamato M, Wada K, Hayashi T et al. Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction. Clin Drug Investig. 2018;38(1): 39-48.
13. Sviridenko NYu, Platonova NM, Molashenko NV et al. Endocrine aspects of amiodarone therapy in clinical practice. (Follow-up and treatment algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. Russian. (Свириденко НЮ, Платонова НМ, Молашенко НВ и др. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский кардиологический журнал. 2021;2:63-71.
14. Lambert MJ, Burger AG; Galeazzi RL, Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 mono- deiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982;55:1058-1065.
15. Mel’nichenko GA, Sviridenko NYu, Molashenko NV et al. Amiodarone-induced thyroid dysfunction: pathigenesis, diagnosis, treatment. Review. Terapevticheskiy arkhiv. 2003;75 (8):92-6. Russian. (Мельниченко ГА, Свириденко НЮ, Молашенко НВ и др. Индуцированная амиодароном дисфункция щитовидной железы (патогенез, диагностика, лечение). Обзор. Терапевтический архив. 2003;75(8):92-96).
16. Tanda ML, Piantanida E, Lai A et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008; 69: 812-818.
17. Raghavan RP, Taylor PN, Bhake R et al. Amiodarone-induced thyrotoxicosis: an overview of UK management. Clin Endocrinol (Oxf). 2012; 77: 936-937.
18. Platonova NM, Molashenko NV, Sviridenko NYu, et al. Amiodarone- associated thyroid dysfunction. Prevalence and correction possibilities. Cardiology. 2004;10:32-38. Russian. (Платонова Н.М., Молашенко Н.В., Свириденко Н.Ю. и др. Амиодарон-ассоциированная дисфункция щитовидной железы. Частота развития и возможности коррекции. Кардиология. 2004; 10: 32-38).
19. Philippou G, Koutras DA, Piperingos G et al. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf). 1992; 36: 573-8.
20. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff Chaikoff effects is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999; 140: 3404-10.
21. Rosene ML, Wittmann G; Drigo RA et al. Inhibition of the Type 2 lodothyronine Deiodinase Underlies the Elevated Plasma TSH Associated with Amiodarone Treatment. Endocrinology. 2010 Dec; 151(12): 5961-5970.
22. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23: 735-751.
23. Batcher EL, Tang XC, Singh BN, et al. (SAFE-T Investigators.) Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007;120:880-885.
24. Benjamens S, Dullaart RPF., Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. European J Endocrinol. 2017; 177: 9-14.
25. Serdiuk SE, Bakalov SA, Golitsyn SP, et al. Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodarone. Terapevticheskiy Arkhiv. 2005; 77 (10): 33-39. Russian. (Сердюк С. Е., Бакалов С. А., Голицын С. П. и др. Частота возникновения и предикторы развития амиодарон-ассоциированных дисфункций щитовидной железы. Терапевтический архив. 2005; (10): 33-39).
26. Grineva EN, Dora SV, Malahova TV, Malahova ZL. Amiodarone impact on thyroid structure and function. Problems of endocrinology. 2008;54(3):17-21. Russian. (Гринева Е.Н., Дора С.В. Малахова Т.В., Малахова З.Л. Влияние амиодарона на струкутуру и функцию щитовидной железы. Проблемы эндокринологии. 2008; 54 (3):17-21).
27. Zhong B, Wang Y, Zhang G; Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and metaanalysis of adverse reactions of amiodarone on the thyroid. Cardiology. 2016; 134: 366-371.